 Why is development of the therapy needed? Is the question relevant and useful?
 Does it contribute to development program or add to medical knowledge?
 What justifies this specific study?
Essential Element 2-Choice of Control and Standard of Care
The choice of the control arm affects multiple aspects of the trial, including its ethical acceptability. Three categories should be evaluated: active comparator, placebo-alone, and placebo-incombination (e.g., in combination with background standard of care or with an active comparator). In addition, all arms of a study will be judged against the standard of care that subjects would or could receive if not enrolled in the research. Active control trials may pose less risk of harm than placebo-controlled trials because all participants have the potential to benefit from the study. Ethical concerns might include biased comparisons, increased overall participant exposure to risk, threats to scientific validity, or concerns regarding availability of active controls in host countries. If the control arm is the "standard of care", this regimen may be assumed to be the current best medical practice and therapeutics.  Is the total number of assessments necessary and not overly burdensome?
 Does the design compromise or expose the subjects to harm in any way?
 Is the study adequately powered to answer the question?
Essential Element 4-Choice of Study Population
The specific choice of subject group may require no explanation beyond the scientific rationale to indicate why it is ethically acceptable to include the proposed subjects (e.g., a well-studied group for whom the risks including the safety profile are well established). However, the principle of fair distribution of benefit and risk for the research, the inclusion of vulnerable populations (who may either be at greater risk or may lack autonomy or capacity to directly consent to the research), or inclusion of other populations who are not necessarily "vulnerable" but who present special challenges may need explanation in the ethics discussion. [14, 15]  Explain the scientific basis for targeting the specific study population.
 Is the targeted group of subjects already burdened by poverty, illness, institutionalization, or age?
 Will the subject recruitment plan be effective in attracting a representative group of volunteers?
Essential Element 5-Potential Benefits and Harms
Every protocol should provide sufficient information to allow assessment of whether there is a reasonable balance of benefit and risk, recognizing that, in early studies of a new therapy, little may be known about either benefit or risk (which is why a study is being proposed). The ethical discussion should focus on the potential risks and benefits that have ethical implications. Interventions that may provide benefit should be at least as advantageous as available alternatives. If there is no direct benefit to the individual, the risks must be reasonable and should be balanced by the benefit to society and the knowledge to be gained. [8]  What are the risks to human research participants?
 What steps have been taken to minimize risks?
 What benefits accrue to the research participants?
 What benefits will the community receive from the conduct of research?
Essential Element 6-Informed
Informed consent is the process for communicating information about the study to potential participants 
Essential element 9-Post-Trial Access
Post-trial access can be any sponsor-provided access to medical benefits after the study has ended. Generally, post-trial access is viewed as favorably affecting the overall risk benefit assessment of the research. However, post-trial access could also provide undue influence on subjects' decisionmaking if it provided too great of a benefit and if there are challenges to continued provision of trial interventions after a trial has ended. How the proper balance is struck should be made clear. [20]  What are the plans to provide study subjects and individuals other than the subjects, with continued access to study interventions or continued access to healthcare treatment and benefits after the study ends?
Essential Element 10-Payment for Participation
The ethical implications of providing any direct compensation to a subject in a clinical trial should be addressed in every protocol. Subjects should be reimbursed for expenses, and participation should be revenue neutral so that lost income should not be a barrier to inclusion in studies. The ethical discussion begins when there is concern about "undue inducement." Although there is no accepted definition of "undue inducement" and there is little agreement about the approach to compensation, it should be clear in the protocol why the approach to compensation is considered warranted. 
